secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-06-16T20:34:58+00:00
Accession:  0001438533-26-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Travere CRO William Rote to retire Feb 2027; CMO Inrig promoted to EVP, Head of R&D
--------------------------------------------------------------------------------

- William Rote, Ph.D., Chief Research Officer, to retire effective Feb 17, 2027, after 10 years.
- Jula Inrig, M.D., current Chief Medical Officer, will assume Rote's responsibilities.
- Effective July 1, 2026, Dr. Inrig becomes EVP, Head of R&D and Chief Medical Officer.
- Travere expects to enter into a consulting arrangement with Dr. Rote post-retirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/tvtx-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer